{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:53:47Z","timestamp":1790016827001,"version":"4.0.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05092-z","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:46:23Z","timestamp":1777117583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progress in cell-based immunotherapies for solid tumors"],"prefix":"10.1007","volume":"17","author":[{"given":"Lifu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"5092_CR1","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1245\/s10434-022-11375-w","volume":"29","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Francescatti AB, Hunt KK. Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3\u20135.8. Ann Surg Oncol. 2022;29:6549\u201358.","journal-title":"Ann Surg Oncol"},{"key":"5092_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.hoc.2019.05.008","volume":"33","author":"JW Atkins","year":"2019","unstructured":"Atkins JW, West K, Kasow KA. Current and Future Cell Therapy Standards and Guidelines. Hematol Oncol Clin North Am. 2019;33:839\u201355.","journal-title":"Hematol Oncol Clin North Am"},{"key":"5092_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41590-019-0452-8","volume":"20","author":"EG Feigal","year":"2019","unstructured":"Feigal EG, DeWitt ND, Cantilena C, Peck C, Stroncek D. At the end of the beginning: immunotherapies as living drugs. Nat Immunol. 2019;20:955\u201362.","journal-title":"Nat Immunol"},{"key":"5092_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44.","journal-title":"Cell Commun Signal"},{"key":"5092_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12964-025-02226-8","volume":"23","author":"G Zhou","year":"2025","unstructured":"Zhou G, et al. Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression. Cell Commun Signal. 2025;23:246.","journal-title":"Cell Commun Signal"},{"key":"5092_CR6","doi-asserted-by":"publisher","first-page":"162635","DOI":"10.1016\/j.cej.2025.162635","volume":"512","author":"Y Gu","year":"2025","unstructured":"Gu Y, et al. Bioengineered extracellular vesicles presenting PD-L1 and Gal-9 to ameliorate new-onset primary ovarian insufficiency (POI). Chem Eng J. 2025;512:162635.","journal-title":"Chem Eng J"},{"key":"5092_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","volume":"17","author":"HM Shepard","year":"2017","unstructured":"Shepard HM, Phillips GL, C DT, Feldmann M. Developments in therapy with monoclonal antibodies and related proteins. Clin Med (Lond). 2017;17:220\u201332.","journal-title":"Clin Med (Lond)"},{"key":"5092_CR8","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","volume":"81","author":"LC Tsao","year":"2021","unstructured":"Tsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Res. 2021;81:4641\u201351.","journal-title":"Cancer Res"},{"key":"5092_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"5092_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng B, et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer. Nature. 2024;634:712\u201320.","journal-title":"Nature"},{"key":"5092_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41586-025-09489-8","volume":"646","author":"NH Knudsen","year":"2025","unstructured":"Knudsen NH, et al. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025;646:953\u201362.","journal-title":"Nature"},{"key":"5092_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","volume":"646","author":"P Datlinger","year":"2025","unstructured":"Datlinger P, et al. Systematic discovery of CRISPR-boosted CAR T cell immunotherapies. Nature. 2025;646:963\u201372.","journal-title":"Nature"},{"key":"5092_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Wolterink K, Wang RGJ, Bos J, G.M.J., Germeraad WT. V. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.","journal-title":"J Hematol Oncol"},{"key":"5092_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12943-024-02151-3","volume":"23","author":"X Zhu","year":"2024","unstructured":"Zhu X, Xue J, Jiang H, Xue D. CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside. Mol Cancer. 2024;23:237.","journal-title":"Mol Cancer"},{"key":"5092_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"5092_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","volume":"11","author":"Z Pang","year":"2023","unstructured":"Pang Z, et al. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11:104.","journal-title":"Biomark Res"},{"key":"5092_CR17","doi-asserted-by":"publisher","first-page":"2033528","DOI":"10.1080\/2162402X.2022.2033528","volume":"11","author":"TLA Wachsmann","year":"2022","unstructured":"Wachsmann TLA, et al. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. Oncoimmunology. 2022;11:2033528.","journal-title":"Oncoimmunology"},{"key":"5092_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5092_CR19","doi-asserted-by":"crossref","unstructured":"Chabannon C, Bonini C. Structure of and Signalling Through Chimeric Antigen Receptor. In: Kr\u00f6ger, N., Gribben, J., Chabannon, C., Yakoub-Agha, I. & Einsele, H, editors. The EBMT\/EHA CAR-T Cell Handbook. Springer Copyright 2022, The Author(s). Cham (CH), 2022, pp 3\u20135.","DOI":"10.1007\/978-3-030-94353-0_1"},{"key":"5092_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18:715\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"5092_CR21","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2016;126:3036\u201352.","journal-title":"J Clin Invest"},{"key":"5092_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","volume":"24","author":"N Muhammad","year":"2022","unstructured":"Muhammad N, et al. A novel TanCAR targeting IL13R\u03b12 and EphA2 for enhanced glioblastoma therapy. Mol Ther Oncolytics. 2022;24:729\u201341.","journal-title":"Mol Ther Oncolytics"},{"key":"5092_CR23","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.","journal-title":"EBioMedicine"},{"key":"5092_CR24","doi-asserted-by":"publisher","first-page":"101804","DOI":"10.1016\/j.xcrm.2024.101804","volume":"5","author":"T Tay","year":"2024","unstructured":"Tay T, et al. Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay. Cell Rep Med. 2024;5:101804.","journal-title":"Cell Rep Med"},{"key":"5092_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/imm.13642","volume":"169","author":"X Yin","year":"2023","unstructured":"Yin X, He L, Guo Z. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it. Immunology. 2023;169:400\u201311.","journal-title":"Immunology"},{"key":"5092_CR26","doi-asserted-by":"publisher","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021;13:eabh0272.","journal-title":"Sci Transl Med"},{"key":"5092_CR27","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","volume":"32","author":"T Ahn","year":"2024","unstructured":"Ahn T, Bae EA, Seo H. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Mol Ther. 2024;32:1617\u201327.","journal-title":"Mol Ther"},{"key":"5092_CR28","doi-asserted-by":"publisher","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","volume":"15","author":"D Meyran","year":"2023","unstructured":"Meyran D, et al. T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med. 2023;15:eabk1900.","journal-title":"Sci Transl Med"},{"key":"5092_CR29","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.immuni.2025.07.018","volume":"58","author":"J Lv","year":"2025","unstructured":"Lv J, et al. Mechanical signaling via \u03b22 integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells. Immunity. 2025;58:2289\u2013e23042210.","journal-title":"Immunity"},{"key":"5092_CR30","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.3390\/curroncol30050378","volume":"30","author":"SR Mucha","year":"2023","unstructured":"Mucha SR, Rajendram P. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. Curr Oncol. 2023;30:5003\u201323.","journal-title":"Curr Oncol"},{"key":"5092_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.56875\/2589-0646.1035","volume":"15","author":"D Yi","year":"2022","unstructured":"Yi D, et al. Next-Generation Chimeric Antigen Receptor T-cells. Hematol Oncol Stem Cell Ther. 2022;15:117\u201321.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"5092_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ymthe.2025.01.047","volume":"33","author":"J Shi","year":"2025","unstructured":"Shi J, et al. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Mol Ther. 2025;33:1073\u201390.","journal-title":"Mol Ther"},{"key":"5092_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","volume":"11","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11:554\u201362.","journal-title":"Front Med"},{"key":"5092_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724\u201334.","journal-title":"Nat Med"},{"key":"5092_CR35","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1016\/j.ymthe.2023.06.015","volume":"31","author":"N Zhang","year":"2023","unstructured":"Zhang N, et al. LIGHT\/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment. Mol Ther. 2023;31:2575\u201390.","journal-title":"Mol Ther"},{"key":"5092_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol. 2022;22:751\u201364.","journal-title":"Nat Rev Immunol"},{"key":"5092_CR37","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00262-023-03413-7","volume":"72","author":"DG Millar","year":"2023","unstructured":"Millar DG, et al. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire. Cancer Immunol Immunother. 2023;72:2375\u201392.","journal-title":"Cancer Immunol Immunother"},{"key":"5092_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, et al. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22:141.","journal-title":"Mol Cancer"},{"key":"5092_CR39","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","volume":"32","author":"J He","year":"2022","unstructured":"He J, et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 2022;32:530\u201342.","journal-title":"Cell Res"},{"key":"5092_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1056\/NEJMc2208623","volume":"387","author":"D Simnica","year":"2022","unstructured":"Simnica D, Kobold S. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med. 2022;387:573.","journal-title":"N Engl J Med"},{"key":"5092_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019\u201327.","journal-title":"Clin Cancer Res"},{"key":"5092_CR42","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-18-3496","volume":"25","author":"TS Nowicki","year":"2019","unstructured":"Nowicki TS, et al. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. Clin Cancer Res. 2019;25:2096\u2013108.","journal-title":"Clin Cancer Res"},{"key":"5092_CR43","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma. Cancer Discov. 2018;8:944\u201357.","journal-title":"Cancer Discov"},{"key":"5092_CR44","doi-asserted-by":"publisher","first-page":"10972","DOI":"10.1073\/pnas.1005802107","volume":"107","author":"MM van Loenen","year":"2010","unstructured":"van Loenen MM, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A. 2010;107:10972\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5092_CR45","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/mt.2014.142","volume":"22","author":"M Bunse","year":"2014","unstructured":"Bunse M, et al. RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther. 2014;22:1983\u201391.","journal-title":"Mol Ther"},{"key":"5092_CR46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi E, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18:807\u201315.","journal-title":"Nat Med"},{"key":"5092_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF. 3rd. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397\u2013405.","journal-title":"Trends Biotechnol"},{"key":"5092_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12141","volume":"257","author":"IM Stromnes","year":"2014","unstructured":"Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev. 2014;257:145\u201364.","journal-title":"Immunol Rev"},{"key":"5092_CR49","doi-asserted-by":"publisher","first-page":"794183","DOI":"10.3389\/fonc.2021.794183","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. TCR-T Immunotherapy: The Challenges and Solutions. Front Oncol. 2021;11:794183.","journal-title":"Front Oncol"},{"key":"5092_CR50","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/mt.2015.60","volume":"23","author":"JH van den Berg","year":"2015","unstructured":"van den Berg JH, et al. Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Mol Ther. 2015;23:1541\u201350.","journal-title":"Mol Ther"},{"key":"5092_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016;6:664\u201379.","journal-title":"Cancer Discov"},{"key":"5092_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396.","journal-title":"Nat Rev Immunol"},{"key":"5092_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21:501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"5092_CR54","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ymthe.2018.11.006","volume":"27","author":"H Echchannaoui","year":"2019","unstructured":"Echchannaoui H, et al. A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo. Mol Ther. 2019;27:261\u201371.","journal-title":"Mol Ther"},{"key":"5092_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.omtm.2022.03.018","volume":"25","author":"J Kath","year":"2022","unstructured":"Kath J, et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Mol Ther Methods Clin Dev. 2022;25:311\u201330.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5092_CR56","doi-asserted-by":"crossref","unstructured":"Huang CS et al. AFP specific T cell receptors with fine-tune affinity induce durable tumor remission in mice and acquire pan-HLA-A*02 recognition. Mol Ther (2026).","DOI":"10.1016\/j.ymthe.2026.01.026"},{"key":"5092_CR57","doi-asserted-by":"crossref","unstructured":"Harly C et al. Human \u03b3\u03b4 T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2. Sci Immunol 6 (2021).","DOI":"10.1126\/sciimmunol.aba9010"},{"key":"5092_CR58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"5092_CR59","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.bbmt.2009.01.019","volume":"15","author":"S Gill","year":"2009","unstructured":"Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transpl. 2009;15:765\u201376.","journal-title":"Biol Blood Marrow Transpl"},{"key":"5092_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119.","journal-title":"J Exp Clin Cancer Res"},{"key":"5092_CR61","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, et al. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.","journal-title":"EBioMedicine"},{"key":"5092_CR62","doi-asserted-by":"crossref","unstructured":"Wrona E, Borowiec M, Potemski P. CAR-NK Cells in the Treatment of Solid Tumors. Int J Mol Sci 22 (2021).","DOI":"10.3390\/ijms22115899"},{"key":"5092_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"5092_CR64","doi-asserted-by":"publisher","first-page":"eadn0881","DOI":"10.1126\/sciadv.adn0881","volume":"10","author":"M Tarannum","year":"2024","unstructured":"Tarannum M, et al. CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer. Sci Adv. 2024;10:eadn0881.","journal-title":"Sci Adv"},{"key":"5092_CR65","doi-asserted-by":"publisher","first-page":"eadn1849","DOI":"10.1126\/sciadv.adn1849","volume":"10","author":"PR Kennedy","year":"2024","unstructured":"Kennedy PR, et al. Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments. Sci Adv. 2024;10:eadn1849.","journal-title":"Sci Adv"},{"key":"5092_CR66","doi-asserted-by":"crossref","unstructured":"Delconte RB et al. Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity. Immunity 57, 1923\u20131938.e1927 (2024).","DOI":"10.1016\/j.immuni.2024.05.021"},{"key":"5092_CR67","doi-asserted-by":"publisher","first-page":"879452","DOI":"10.3389\/fimmu.2022.879452","volume":"13","author":"WK Bae","year":"2022","unstructured":"Bae WK, et al. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. Front Immunol. 2022;13:879452.","journal-title":"Front Immunol"},{"key":"5092_CR68","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025;31:1987\u201393.","journal-title":"Nat Med"},{"key":"5092_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","volume":"31","author":"F Fang","year":"2017","unstructured":"Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37\u201354.","journal-title":"Semin Immunol"},{"key":"5092_CR70","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41:272\u2013e287279.","journal-title":"Cancer Cell"},{"key":"5092_CR71","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.1038\/s41467-025-63863-8","volume":"16","author":"F Liu","year":"2025","unstructured":"Liu F, et al. Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice. Nat Commun. 2025;16:8809.","journal-title":"Nat Commun"},{"key":"5092_CR72","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/bloodadvances.2018019059","volume":"2","author":"X Zhao","year":"2018","unstructured":"Zhao X, et al. NK cell development in a human stem cell niche: KIR expression occurs independently of the presence of HLA class I ligands. Blood Adv. 2018;2:2452\u201361.","journal-title":"Blood Adv"},{"key":"5092_CR73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.","journal-title":"Mol Cancer"},{"key":"5092_CR74","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21:1089\u2013108.","journal-title":"Cell Mol Immunol"},{"key":"5092_CR75","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21:835\u201347.","journal-title":"Nat Immunol"},{"key":"5092_CR76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B C\u00f3zar","year":"2021","unstructured":"C\u00f3zar B, et al. Tumor-Infiltrating Natural Killer Cells. Cancer Discov. 2021;11:34\u201344.","journal-title":"Cancer Discov"},{"key":"5092_CR77","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2326-6066.CIR-16-0152","volume":"5","author":"LS Peng","year":"2017","unstructured":"Peng LS, et al. Tumor-Associated Monocytes\/Macrophages Impair NK-Cell Function via TGF\u03b21 in Human Gastric Cancer. Cancer Immunol Res. 2017;5:248\u201356.","journal-title":"Cancer Immunol Res"},{"key":"5092_CR78","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","volume":"10","author":"I Terr\u00e9n","year":"2019","unstructured":"Terr\u00e9n I, Orrantia A, Vitall\u00e9 J, Zenarruzabeitia O, Borrego F. NK Cell Metabolism and Tumor Microenvironment. Front Immunol. 2019;10:2278.","journal-title":"Front Immunol"},{"key":"5092_CR79","doi-asserted-by":"publisher","first-page":"e0211538","DOI":"10.1371\/journal.pone.0211538","volume":"14","author":"CD Cluxton","year":"2019","unstructured":"Cluxton CD, et al. Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade. PLoS ONE. 2019;14:e0211538.","journal-title":"PLoS ONE"},{"key":"5092_CR80","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1186\/s12967-024-05903-3","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. CAR-armored-cell therapy in solid tumor treatment. J Transl Med. 2024;22:1076.","journal-title":"J Transl Med"},{"key":"5092_CR81","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","volume":"121","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology. 2007;121:258\u201365.","journal-title":"Immunology"},{"key":"5092_CR82","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1182\/blood-2012-03-415364","volume":"119","author":"S Gill","year":"2012","unstructured":"Gill S, et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012;119:5758\u201368.","journal-title":"Blood"},{"key":"5092_CR83","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.molimm.2023.01.010","volume":"155","author":"C Guo","year":"2023","unstructured":"Guo C, et al. Engagement of an optimized lentiviral vector enhances the expression and cytotoxicity of CAR in human NK cells. Mol Immunol. 2023;155:91\u20139.","journal-title":"Mol Immunol"},{"key":"5092_CR84","doi-asserted-by":"crossref","unstructured":"Christodoulou I et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer 9 (2021).","DOI":"10.1101\/2021.09.23.461509"},{"key":"5092_CR85","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018;23:181\u2013e192185.","journal-title":"Cell Stem Cell"},{"key":"5092_CR86","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41467-023-40220-1","volume":"14","author":"BD Huisman","year":"2023","unstructured":"Huisman BD, et al. High-throughput characterization of HLA-E-presented CD94\/NKG2x ligands reveals peptides which modulate NK cell activation. Nat Commun. 2023;14:4809.","journal-title":"Nat Commun"},{"key":"5092_CR87","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/1097-0142(197202)29:2<472::AID-CNCR2820290235>3.0.CO;2-U","volume":"29","author":"SA Rosenberg","year":"1972","unstructured":"Rosenberg SA, Fox E, Churchill WH. Spontaneous regression of hepatic metastases from gastric carcinoma. Cancer. 1972;29:472\u20134.","journal-title":"Cancer"},{"key":"5092_CR88","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, et al. Intraepithelial CD8\u2009+\u2009tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5092_CR89","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960\u20134.","journal-title":"Science"},{"key":"5092_CR90","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","volume":"41","author":"\u00d6 Met","year":"2019","unstructured":"Met \u00d6, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. Semin Immunopathol. 2019;41:49\u201358.","journal-title":"Semin Immunopathol"},{"key":"5092_CR91","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/2326-6066.CIR-17-0467","volume":"6","author":"R Andersen","year":"2018","unstructured":"Andersen R, et al. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. Cancer Immunol Res. 2018;6:222\u201335.","journal-title":"Cancer Immunol Res"},{"key":"5092_CR92","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20:434\u201344.","journal-title":"Clin Cancer Res"},{"key":"5092_CR93","doi-asserted-by":"publisher","first-page":"115713","DOI":"10.1016\/j.addr.2025.115713","volume":"227","author":"D Bas\u00edlio-Queir\u00f3s","year":"2025","unstructured":"Bas\u00edlio-Queir\u00f3s D, Rivi\u00e8re I, van der Stegen SJC, Lachmann N. iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches. Adv Drug Deliv Rev. 2025;227:115713.","journal-title":"Adv Drug Deliv Rev"},{"key":"5092_CR94","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928\u201333.","journal-title":"Nat Biotechnol"},{"key":"5092_CR95","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","volume":"22","author":"NG Kooreman","year":"2018","unstructured":"Kooreman NG, et al. Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. Cell Stem Cell. 2018;22:501\u2013e513507.","journal-title":"Cell Stem Cell"},{"key":"5092_CR96","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, et al. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. Cell Stem Cell. 2020;27:224\u2013e237226.","journal-title":"Cell Stem Cell"},{"key":"5092_CR97","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li N, et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23:117.","journal-title":"Mol Cancer"},{"key":"5092_CR98","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen Y, et al. CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605.","journal-title":"Biomed Pharmacother"},{"key":"5092_CR99","doi-asserted-by":"crossref","unstructured":"Zhou G et al. Vaginal Microbial Environment Skews Macrophage Polarization and Contributes to Cervical Cancer Development. J Immunol Res. 2022, 3525735 (2022).","DOI":"10.1155\/2022\/3525735"},{"key":"5092_CR100","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43:546\u201363.","journal-title":"Trends Immunol"},{"key":"5092_CR101","doi-asserted-by":"publisher","first-page":"645","DOI":"10.17305\/bb.2025.11971","volume":"26","author":"G Zhou","year":"2025","unstructured":"Zhou G, et al. Adipose-derived MSC extracellular vesicles ameliorate sepsis by reprogramming macrophages via miR-21-5p targeting PELI1. Biomol Biomed. 2025;26:645\u201361.","journal-title":"Biomol Biomed"},{"key":"5092_CR102","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23:86.","journal-title":"Cancer Cell Int"},{"key":"5092_CR103","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12672-025-04276-3","volume":"17","author":"OQB Allela","year":"2025","unstructured":"Allela OQB, et al. Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance. Discov Oncol. 2025;17:113.","journal-title":"Discov Oncol"},{"key":"5092_CR104","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s43018-024-00798-x","volume":"5","author":"M Arias-Badia","year":"2024","unstructured":"Arias-Badia M, Chang R, Fong L. \u03b3\u03b4 T cells as critical anti-tumor immune effectors. Nat Cancer. 2024;5:1145\u201357.","journal-title":"Nat Cancer"},{"key":"5092_CR105","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/bs.acr.2024.05.004","volume":"164","author":"A Kumar","year":"2024","unstructured":"Kumar A, Emdad L, Das SK, Fisher PB. Recent advances and progress in immunotherapy of solid cancers. Adv Cancer Res. 2024;164:111\u201390.","journal-title":"Adv Cancer Res"},{"key":"5092_CR106","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"5092_CR107","doi-asserted-by":"crossref","unstructured":"Erasha AM, El-Gendy H, Aly AS, Fern\u00e1ndez-Ortiz M, Sayed RKA. The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and Inflammasomes. Int J Mol Sci 26 (2025).","DOI":"10.3390\/ijms26062716"},{"key":"5092_CR108","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.","journal-title":"J Immunother Cancer"},{"key":"5092_CR109","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"5092_CR110","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","volume":"65","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13\u201327.","journal-title":"Semin Cancer Biol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05092-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:02:15Z","timestamp":1780970535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05092-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5092"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05092-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"872"}}